{
    "xml": "<topic id=\"PHP4142\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/gliclazide\" basename=\"gliclazide\" title=\"GLICLAZIDE\">\n<title>GLICLAZIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_271\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/sulfonylureas/gliclazide\">Gliclazide</xref>\n</p>\n<data name=\"vtmid\">325238000</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_606020038\" title=\"Sulfonylureas\">Sulfonylureas</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34524\" title=\"SULFONYLUREAS\" namespace=\"/drug-classes/sulfonylureas\">SULFONYLUREAS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP59217\" outputclass=\"indicationsAndDose\" rev=\"1.20\" parent=\"/drugs/gliclazide\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Type 2 diabetes mellitus</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by mouth using immediate-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 40&#8211;80&#8239;mg daily, adjusted according to response, (by mouth) increased if necessary up to 160&#8239;mg once daily, dose to be taken with breakfast, doses higher than 160&#8239;mg to be given in divided doses; maximum 320&#8239;mg per day.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By mouth using modified-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 30&#8239;mg daily, dose to be taken with breakfast, adjust dose according to response every 4 weeks (after 2 weeks if no decrease in blood glucose); maximum 120&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseEquivalence\">\n<title>Dose equivalence and conversion</title>\n<p>Gliclazide modified release 30&#8239;mg may be considered to be approximately equivalent in therapeutic effect to standard formulation gliclazide 80&#8239;mg.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59294\" outputclass=\"contraindications\" rev=\"1.17\" parent=\"/drugs/gliclazide\">\n<title>Contra-indications</title>\n<body>\r\n<section outputclass=\"contraindications\">\r\n<p>\r\n<ph outputclass=\"contraindication\">Avoid where possible in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP59212\" outputclass=\"interactions\" rev=\"1.10\" parent=\"/drugs/gliclazide\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (antidiabetics).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59198\" outputclass=\"pregnancy\" parent=\"/drugs/gliclazide\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59323\" outputclass=\"breastFeeding\" parent=\"/drugs/gliclazide\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;theoretical possibility of hypoglycaemia in the infant.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59164\" outputclass=\"renalImpairment\" parent=\"/drugs/gliclazide\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>If necessary, gliclazide which is principally metabolised in the liver, can be used in renal impairment but careful monitoring of blood-glucose concentration is essential.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP4142-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/gliclazide\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76205\" title=\"Tablet\" namespace=\"/drugs/gliclazide/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76211\" title=\"Modified-release tablet\" namespace=\"/drugs/gliclazide/modified-release-tablet\">Modified-release tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78107\" namespace=\"/treatment-summaries/insulins-and-anti-diabetic-drugs\" title=\"Insulins and anti-diabetic drugs\" count=\"1\" rel=\"backlink\">Insulins and anti-diabetic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_271\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/sulfonylureas/gliclazide\" title=\"Gliclazide\" count=\"1\" rel=\"link\">Gliclazide</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34524\" namespace=\"/drug-classes/sulfonylureas\" title=\"SULFONYLUREAS\" count=\"1\" rel=\"link\">SULFONYLUREAS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76205\" namespace=\"/drugs/gliclazide/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76211\" namespace=\"/drugs/gliclazide/modified-release-tablet\" title=\"Modified-release tablet\" count=\"1\" rel=\"link\">Modified-release tablet</xref>\n</links>\n</topic>",
    "id": "PHP4142",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/gliclazide",
    "basename": "gliclazide",
    "title": "GLICLAZIDE",
    "interactants": [
        {
            "id": "bnf_int_271",
            "label": "Gliclazide"
        }
    ],
    "vtmid": "325238000",
    "drugClassification": [
        "Sulfonylureas"
    ],
    "inheritsFromClass": [
        "SULFONYLUREAS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Type 2 diabetes mellitus",
                        "html": "Type 2 diabetes mellitus"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using modified-release medicines"
                    ],
                    "textContent": "By mouth using modified-release medicines",
                    "html": "By mouth using modified-release medicines"
                },
                "adult": [
                    {
                        "textContent": "Initially 40&#8211;80 mg daily, adjusted according to response, (by mouth) increased if necessary up to 160 mg once daily, dose to be taken with breakfast, doses higher than 160 mg to be given in divided doses; maximum 320 mg per day.",
                        "html": "<p>Initially 40&#8211;80&#8239;mg daily, adjusted according to response, (by mouth) increased if necessary up to 160&#8239;mg once daily, dose to be taken with breakfast, doses higher than 160&#8239;mg to be given in divided doses; maximum 320&#8239;mg per day.</p>"
                    },
                    {
                        "textContent": "Initially 30 mg daily, dose to be taken with breakfast, adjust dose according to response every 4 weeks (after 2 weeks if no decrease in blood glucose); maximum 120 mg per day.",
                        "html": "<p>Initially 30&#8239;mg daily, dose to be taken with breakfast, adjust dose according to response every 4 weeks (after 2 weeks if no decrease in blood glucose); maximum 120&#8239;mg per day.</p>"
                    }
                ]
            }
        ],
        "doseEquivalence": [
            {
                "type": "doseEquivalence",
                "title": "Dose equivalence and conversion",
                "textContent": "Gliclazide modified release 30 mg may be considered to be approximately equivalent in therapeutic effect to standard formulation gliclazide 80 mg.",
                "html": "<p>Gliclazide modified release 30&#8239;mg may be considered to be approximately equivalent in therapeutic effect to standard formulation gliclazide 80&#8239;mg.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Avoid where possible in Acute porphyrias",
                "html": "Avoid where possible in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (antidiabetics).",
                "html": "<p>Appendix 1 (antidiabetics).</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.",
                "html": "<p>The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;theoretical possibility of hypoglycaemia in the infant.",
                "html": "<p>Avoid&#8212;theoretical possibility of hypoglycaemia in the infant.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "If necessary, gliclazide which is principally metabolised in the liver, can be used in renal impairment but careful monitoring of blood-glucose concentration is essential.",
                "html": "<p>If necessary, gliclazide which is principally metabolised in the liver, can be used in renal impairment but careful monitoring of blood-glucose concentration is essential.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76205",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76211",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78107",
                "label": "Insulins and anti-diabetic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_271",
                "label": "Gliclazide",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34524",
                "label": "SULFONYLUREAS",
                "type": "drugClass"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76205",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76211",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            }
        ]
    }
}